France is represented in JPIAMR by The French National Research funding Agency (ANR) and the French National Institute of Health and Medical Research (Inserm).
Inserm is a public scientific and technological institution, placed under the dual supervision of the Ministry of Health and the Ministry of Research. Dedicated to biological, medical and human health research, it covers the entire AMR field from fundamental and laboratory research to the patient’s bedside. On the international scene, Inserm partners with most large research institutions committed to scientific and medical progress. Inserm is the only French public scientific and technological institute (Research Performing Organisation) to focus entirely on human health.
ANR is a research funding organization and aims to bring more flexibility to the French research system, foster new collaborations and cutting edge-strategies for acquiring new knowledge. By identifying priority research areas and supporting private-public collaborations, it also aims to enhance the general level of competitiveness of both the French research system and the French economy. International activities are one of the priorities of ANR.
National AMR research program and activities
AMR Research program
- France’s Antibiotic Resistance Priority Research Program (PPR) coordinated by Inserm (2019 – 2023): 40M€. This program includes the funding of research projects, the funding of networks to structure the scientific community and connect the national researchers with researchers in low and middle income countries, and the funding of position of excellence for early carrier scientists and senior researchers.
National AMR research calls
- ANR Generic call for proposals 2022-2023
- National Call for Innovation in the Health sector: One Health Innovation Biocluster on Infectious diseases (Lyon) awarded in May 2023.
- Participation in the 2022 JPIAMR transnational call for projects on “Therapeutics”
- Participation in the 2022 JPIAMR transnational network call 202 on “Diagnostics and Surveillance”
- Participation in the 2023 JPIAMR transnational call for projects on “Therapeutics”
Activities on AMR actions at national level
- A resource portal for AMR has been set up
- In the framework of the priority program, three platforms have already been launched in 2021 to promote cooperation and resource sharing within the AMR research community:
- – ABRomics-PF: a numerical plateform on antibiotic resistance to store, integrate, analyse and share multi-omics data
- – Promise: professional community network on antibiotic resistance
- – DOSA: digital observatory of Social dimensions of antimicrobial resistance
- In the framework of the priority program, eight research chairs for young researchers, and one research chair for senior researcher have been awarded in November 2022.
- In the framework of the French Presidency of the European Union
- High-level one health ministerial conference on antimicrobial resistance, March, 7 2022
- International symposium on research on Antimicrobial Resistance organised June 7, 2022
- National conference on Antibiotic resistance, Nov 22, 2022 (ANR/ INSERM/ ITMO I3M)
- A Thematic report on Antibiotic resistance published in November 2022 (ANR)
- Coordination of the 2024-2028 EU-JAMRAI2 coordinated by the French Ministry of Health and INSERM
National action plans
- Écoantibio 2: Plan national de réduction des risques d’antibiorésistance en médecine vétérinaire (2017-2021); the French national plan for the reduction of the risks of antimicrobial resistance in veterinary medicine
- Preparation of the EcoAntibio3 roadmap in progress.
- Preparation of the intersectoral roadmap against AMR in progress.
Management Board representative
- Philippe Bouvet, Agence Nationale de Recherche (ANR)
- Marie-Cecile Ploy, RESINFIT, University of Limoges and lnserm